Shares of Bicara Therapeutics (BCAX) (BCRX) after moving lower after Johnson & Johnson (JNJ) reported Phase 1b/2 data for amivantamab in patients with head and neck squamous cell carcinoma. J&J’s data show tumor shrinkage was observed in 82% of patients. Bicara is developing ficerafusp alfa combined with pembrolizumab as a treatment for head and neck squamous cell carcinoma. The stock in midday trading is down 20% to $14.52.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Bicara Therapeutics management to meet with Cantor Fitzgerald
- Bicara Therapeutics announces ficerafusp alfa granted BTD by U.S. FDA
- Bicara Therapeutics files $400M mixed securities shelf
- Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating
- Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation Upside